A class of substituted benzoylpiperazine compounds and their application in the preparation of anti-Chikungunya virus drugs
By designing and synthesizing substituted benzoylpiperazine compounds, the problem of lacking effective anti-Chikungunya virus drugs has been solved, achieving effective inhibition of CHIKV and providing a better treatment option.
Patent Information
- Application Number
- CN202410312574.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-11-24
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2040-11-24
AI Technical Summary
Currently, there are no effective drugs to treat Chikungunya virus. Existing treatments are mainly symptomatic and cannot eradicate the joint pain and stiffness caused by the virus.
A class of substituted benzoylpiperazine compounds was developed and prepared into pharmaceutical salts through specific structural design. These salts are used to prepare anti-Chikungunya virus drugs and exhibit good anti-CHIKV activity.
The prepared compound showed good inhibitory effects against CHIKV, with an infection rate of less than 50%, and can be used as an effective anti-Chikungunya virus drug.
Smart Images

Figure CN118324717B_ABST
Abstract
Description
[0001] This application is a divisional application of the following original divisional application: filed on November 24, 2020, application number 202210922028.5, entitled "A Class of Substituted Benzoylpiperazine Compounds and Their Use in the Preparation of Anti-Chikungunya Virus Drugs"; that original divisional application is a divisional application of the following parent application: filed on November 24, 2020, application number 202011329695.X, entitled "A Class of Substituted Benzoylpiperazine Compounds and Their Use in the Preparation of Anti-Chikungunya Virus Drugs". This application is a further divisional application filed by the applicant in accordance with the examination opinion on unity of invention in the first examination opinion of the original divisional application. Technical Field
[0002] This invention belongs to the field of pharmaceutical technology, specifically relating to a class of substituted benzoylpiperazine compounds and their application in the preparation of anti-Chikungunya virus drugs. Background Technology
[0003] Chikungunya virus (CHIKV) belongs to the genus CHIKV in the family Phaeoviridae. Humans and non-human primates are the main hosts of CHIKV. Chikungunya virus can also be called chikungunya fever. Chikungunya fever is an acute febrile infectious disease transmitted through mosquito bites. This viral disease was previously mainly distributed in tropical and subtropical regions of Africa, South Asia, and Southeast Asia. In recent years, due to factors such as global warming and modern transportation, the virus has shown a continuous trend of outbreaks and spread. The first imported case of chikungunya fever was detected at the Shenzhen port on November 19, 2009. After infection with the chikungunya virus, patients experience severe muscle and joint pain, accompanied by fever, nausea, and vomiting. After the acute phase, most patients' joint pain and stiffness completely recover. Some patients experience persistent joint pain and stiffness for weeks to months, or even more than three years. A few patients suffer from sequelae such as impaired joint function, seriously endangering human health. Currently, there are no approved vaccines or specific antiviral drugs for chikungunya fever. Treatment mainly involves symptomatic relief such as fever reduction and pain relief. Summary of the Invention
[0004] The first objective of this invention is to provide a class of substituted benzoylpiperazine compounds.
[0005] A second objective of this invention is to provide the aforementioned substituted benzoylpiperazine compound and its use in the preparation of anti-Chikungunya virus drugs.
[0006] To achieve the above objectives, the technical solution adopted by the present invention is as follows:
[0007] The first aspect of the present invention provides a class of substituted benzoylpiperazine compounds or pharmaceutical salts thereof, having one of the following structures:
[0008]
[0009]
[0010] R1, R2, R3, R4, and R5 are each independently selected from hydrogen, C1-C10 alkyl, C1-C10 alkoxy, and halogens (fluorine, chlorine, bromine, iodine);
[0011] R6, R7, R8, R9, R 10 R 11 R 12 R 13 R 14 R 15 Each is independently selected from hydrogen, hydroxyl, halogen, C1-C10 alkyl, and C1-C10 alkoxy;
[0012] Alternatively, R8 and R9 can form 3- to 7-membered rings with C and O (such as 1,3-dioxolane);
[0013] R 16 R 17 R 18 R 19 R 20 Each is independently selected from hydrogen, C1-C10 alkyl, C1-C10 alkoxy, and halogen.
[0014] Preferably, the substituted benzoylpiperazine compound has one of the following structures:
[0015]
[0016]
[0017] A second aspect of the present invention provides the use of a substituted benzoylpiperazine compound or a pharmaceutical salt thereof in the preparation of an anti-Chikungunya virus drug, said substituted benzoylpiperazine compound having the following general structural formula:
[0018]
[0019] R1, R2, R3, R4, and R5 are each independently selected from hydrogen, hydroxyl, C1-C10 alkyl, C1-C10 alkoxy, and halogen;
[0020] X is selected from C or N;
[0021] Y is selected from one of the following groups:
[0022]
[0023] R6, R7, R8, R9, R 10R 11 R 12 R 13 R 14 R 15 Each is independently selected from hydrogen, hydroxyl, halogen, C1-C10 alkyl, and C1-C10 alkoxy;
[0024] Alternatively, R8 and R9 can form 3- to 7-membered rings with C and O (such as 1,3-dioxolane);
[0025] R 16 R 17 R 18 R 19 R 20 Each is independently selected from hydrogen, C1-C10 alkyl, C1-C10 alkoxy, and halogen.
[0026] Preferably, the substituted benzoylpiperazine compound has one of the following structures:
[0027]
[0028] R1, R2, R3, R4, and R5 are each independently selected from hydrogen, C1-C10 alkyl, C1-C10 alkoxy, and halogen;
[0029] R6, R7, R8, R9, R 10 R 11 R 12 R 13 R 14 R 15 Each is independently selected from hydrogen, hydroxyl, halogen, C1-C10 alkyl, and C1-C10 alkoxy;
[0030] Alternatively, R8 and R9 can form 3- to 7-membered rings with C and O (such as 1,3-dioxolane);
[0031] R 16 R 17 R 18 R 19 R 20 Each is independently selected from hydrogen, C1-C10 alkyl, C1-C10 alkoxy, and halogen.
[0032] Most preferably, the substituted benzoylpiperazine compound has one of the following structures:
[0033]
[0034]
[0035]
[0036]
[0037] By adopting the above technical solution, the present invention has the following advantages and beneficial effects:
[0038] The substituted benzoylpiperazine compounds of the present invention have good anti-CHIKV activity with an infection rate of less than 50%. The compounds prepared in the embodiments of the present invention all show good inhibitory activity against CHIKV and can be used as anti-Chikungunya virus drugs. Detailed Implementation
[0039] To more clearly illustrate the present invention, the following description, in conjunction with preferred embodiments, further clarifies the invention. Those skilled in the art should understand that the specific descriptions below are illustrative rather than restrictive, and should not be construed as limiting the scope of protection of the present invention.
[0040] The materials used in this invention embodiment are as follows: Bruker Spectmspin AC-P300 (Bruker, Switzerland); AC-P600 nuclear magnetic resonance spectrometer (Bruker, Switzerland); Agilent 6120 LC-MS mass spectrometer (Agilent Technologies, USA); GF254 silica gel plates (Yantai Huanghai Chemical, China); dark box UV analyzer (ZF-20D model); rotary evaporator (Buchi Rotavapor R-3 model); SHB-III circulating multi-purpose vacuum pump; vacuum drying oven (DZF-6021 model); ultrasonic cleaner (KQ-500E model); reagents (analytical grade) and raw materials used in the experiment were purchased from Anaiji Reagent Co., Ltd., Bailingwei Technology Co., Ltd., Bide Pharmaceutical Technology Co., Ltd., and Tansuo Platform, etc.
[0041] Example 1
[0042] Preparation of compound 1B-1:
[0043]
[0044] 3,4,5-Trimethoxybenzoic acid (compound 1) (100.0 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask and dissolved in DCM (10.0 mL, dichloromethane). Then, 1-(2-chlorophenyl)piperazine (120.0 mg, 0.6 mmol), DCC (124.0 mg, 0.6 mmol, N,N'-dicyclohexylcarboimide), and DMAP (244.0 mg, 2.0 mmol) were added sequentially. The mixture was stirred at room temperature for 6 h, and the solution changed from clear to turbid. TLC was used to detect the change (DCM:MeOH = 10:1). After the reaction was complete, the mixture was filtered, and the filtrate was evaporated to dryness under reduced pressure. Recrystallization with 95% EtOH yielded compound 1A-1 (111.0 mg, yield: 56%).
[0045] Compound 1A-1 (100.0 mg, 0.3 mmol) was placed in a 100 mL round-bottom three-necked flask. Anhydrous DCM (10.0 mL) was added under anhydrous and oxygen-free argon atmosphere. A DCM solution of BBr3 (6.0 mL, 3.0 mmol) was added dropwise at a constant rate of two drops per second at -30 °C. After the addition was complete, the reaction apparatus was moved to room temperature and stirred overnight. TLC was used for monitoring (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction. The mixture was stirred at room temperature for 1 h. The presence of solid precipitate was then observed. If solid precipitate was present, the mixture was filtered, and the filter cake was dried in an oven. If no solid precipitate was present, the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, and evaporated to dryness. The organic phase was then recrystallized with DCM or EtOH to obtain compound 1B-1.
[0046] Example 2
[0047] Preparation of compound 1B-2:
[0048]
[0049] The 1-(2-chlorophenyl)piperazine used in Example 1 was replaced with 1-(3-chlorophenyl)piperazine (120.0 mg, 0.6 mmol), and all other procedures were the same as in Example 1, to obtain compound 1A-2 (123.0 mg, yield: 61%). The preparation of compound 1B-2 was performed in accordance with the preparation of compound 1B-1 in Example 1.
[0050] Example 3
[0051]
[0052] The 1-(2-chlorophenyl)piperazine used in Example 1 was replaced with 1-(2,3-dichlorophenyl)piperazine (140.0 mg, 0.6 mmol), and all other procedures were the same as in Example 1, to obtain compound 1A-3 (107.0 mg, yield: 58%). The preparation of compound 1B-3 was performed in accordance with the preparation of compound 1B-1 in Example 1.
[0053] Example 4
[0054]
[0055] 3,4,5-Trimethoxybenzoic acid (compound 1) (100.0 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, 4,4'-difluorodiphenylmethylpiperazine (173.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound 1A-4 (118.0 mg, yield: 60%) was obtained.
[0056] The preparation of compound 1B-4 is based on the preparation of compound 1B-1 in Example 1.
[0057] Example 5
[0058]
[0059]
[0060] 3,4,5-Trimethoxybenzoic acid (compound 1) (100.0 mg, 0.5 mmol), N-Boc-piperazine (150.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 ml, 2.0 mmol) were added. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 ml of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. The mixture was filtered, and the filter cake was recrystallized from 95% EtOH to obtain intermediate a. The product was weighed and dissolved in hydrochloric acid-ethyl acetate solution at a 1:3 equivalent ratio. The mixture was stirred at room temperature, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, the mixture was filtered, and the product was recrystallized from 95% EtOH to obtain intermediate b.
[0061] Intermediate b (140.0 mg, 0.5 mmol), 2,3-dichlorobenzoic acid (115.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol) and DIEA (1.0 ml, 2.0 mmol) were administered in the same manner as compound 1A-4 to give compound 1A-5 121.0 mg (yield: 59%).
[0062] The preparation of compound 1B-5 is the same as that of compound 1B-1 in Example 1.
[0063] Example 6
[0064]
[0065] The 2,3-dichlorobenzoic acid used in Example 5 was replaced with 3,4-dichlorobenzoic acid (115.0 mg, 0.6 mmol), and all other procedures were the same as in Example 5, to obtain compound 1A-6 (115.0 mg, yield: 58%). The preparation of compound 1B-6 was performed in accordance with the preparation of compound 1B-1 in Example 1.
[0066] Example 7
[0067]
[0068] The 2,3-dichlorobenzoic acid used in Example 5 was replaced with 3,4,5-trifluorobenzoic acid (110.0 mg, 0.6 mmol), and all other procedures were the same as in Example 5, to obtain compound 1A-7 (120.0 mg, yield: 65%). The preparation of compound 1B-7 was performed in accordance with the preparation of compound 1B-1 in Example 1.
[0069] Example 8
[0070]
[0071] By replacing 2,3-dichlorobenzoic acid used in Example 5 with trans-cinnamic acid (100.0 mg, 0.6 mmol), and otherwise following the procedure of Example 5, compound 1A-8 (116.0 mg, yield: 59%) was obtained. The preparation of compound 1B-8 was performed in accordance with the preparation of compound 1B-1 in Example 1.
[0072] Example 9
[0073]
[0074] By replacing 2,3-dichlorobenzoic acid used in Example 5 with phenoxyacetic acid (100.0 mg, 0.6 mmol), and otherwise following the procedure of Example 5, compound 1A-9 (130.0 mg, yield: 75%) was obtained. The preparation of compound 1B-9 was performed in accordance with the preparation of compound 1B-1 in Example 1.
[0075] Example 10
[0076]
[0077] The 2,3-dichlorobenzoic acid used in Example 5 was replaced with 2,4-dichlorophenoxyacetic acid (135.0 mg, 0.6 mmol), and all other procedures were the same as in Example 5, to obtain compound 1A-10 (109.0 mg, yield: 58%). The preparation of compound 1B-10 was performed in accordance with the preparation of compound 1B-1 in Example 1.
[0078] Example 11
[0079]
[0080] Compound c (163.0 mg, 0.6 mmol) was placed in a 100 mL round-bottom flask and dissolved in DMF (10.0 mL). Then, 3,4,5-trimethoxybenzoic acid (compound 1) (100.0 mg, 0.5 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 2 h and monitored by TLC (DCM:MeOH = 10:1). Once the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, 1A-11 (138.0 mg, yield: 78%) was obtained.
[0081] The preparation of compound 1B-11 is the same as that of compound 1B-1 in Example 1.
[0082] Example 12
[0083]
[0084] 2,3,4-Trimethoxybenzoic acid (compound 4) (100.0 mg, 0.5 mmol), 1-(2-chlorophenyl)piperazine (120.0 mg, 0.6 mmol), DCC (124.0 mg, 0.6 mmol), DMAP (244.0 mg, 2.0 mmol), were administered in the same manner as 1A-1 in Example 1 to obtain compound 1C-1 (102.0 mg, yield: 48%).
[0085] Compound 1C-1 (100.0 mg, 0.3 mmol), BBr3 in DCM solution (6.0 ml, 3.0 mmol), were prepared using the same method as compound 1B-1 in Example 1 to obtain compound 1D-1.
[0086] Example 13
[0087]
[0088] By replacing the 1-(2-chlorophenyl)piperazine used in Example 12 with 1-(3-chlorophenyl)piperazine (120.0 mg, 0.6 mmol), and otherwise referring to Example 12, compound 1C-2 (110.0 mg, yield: 54%) was obtained.
[0089] The preparation of compound 1D-2 is based on the preparation of compound 1D-1 in Example 12.
[0090] Example 14
[0091]
[0092] The compound 1C-3 (109.0 mg, yield: 50%) was obtained by replacing 1-(2-chlorophenyl)piperazine (140.0 mg, 0.6 mmol) in Example 12 with 1-(2-chlorophenyl)piperazine (140.0 mg, 0.6 mmol) in the same manner as in Example 12.
[0093] The preparation of compound 1D-3 is based on the preparation of compound 1D-1 in Example 12.
[0094] Example 15
[0095]
[0096] 2,3,4-Trimethoxybenzoic acid (compound 4) (100.0 mg, 0.5 mmol), 4,4'-difluorodiphenylmethylpiperazine (173.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), DIEA (1.0 ml, 2.0 mmol), were prepared by the same method as 1A-4 in Example 4 to obtain compound 1C-4 (117.0 mg, yield: 58%).
[0097] The preparation of compound 1D-4 is based on the preparation of compound 1D-1 in Example 12.
[0098] Example 16
[0099]
[0100]
[0101] Take 2,3,4-trimethoxybenzoic acid (compound 4) (100.0 mg, 0.5 mmol), N-Boc-piperazine (150.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 ml, 2.0 mmol) and proceed with the same method as intermediate b in Example 5 to obtain intermediate e.
[0102] Weigh intermediate e (140.0 mg, 0.5 mmol), 2,3-dichlorobenzoic acid (115.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 ml, 2.0 mmol), and proceed as in Example 4, 1A-4, to obtain 1C-5 (135.0 mg, yield: 79%).
[0103] The preparation of compound 1D-5 is based on the preparation of compound 1D-1 in Example 12.
[0104] Example 17
[0105]
[0106] By replacing 2,3-dichlorobenzoic acid used in Example 16 with 3,4-dichlorobenzoic acid (115.0 mg, 0.6 mmol), and otherwise referring to Example 16, compound 1C-6 (124.0 mg, yield: 68%) was obtained.
[0107] The preparation of compound 1D-6 is based on the preparation of compound 1D-1 in Example 12.
[0108] Example 18
[0109]
[0110] By replacing 2,3-dichlorobenzoic acid used in Example 16 with 3,4,5-trifluorobenzoic acid (110.0 mg, 0.6 mmol), and otherwise referring to Example 16, compound 1C-7 (132.0 mg, yield: 70%) was obtained.
[0111] The preparation of compound 1D-7 is based on the preparation of compound 1D-1 in Example 12.
[0112] Example 19
[0113]
[0114] By replacing 2,3-dichlorobenzoic acid used in Example 16 with trans-cinnamic acid (100.0 mg, 0.6 mmol), and otherwise referring to Example 16, compound 1C-8 (130.0 mg, yield: 78%) was obtained.
[0115] The preparation of compound 1D-8 is based on the preparation of compound 1D-1 in Example 12.
[0116] Example 20
[0117]
[0118] By replacing 2,3-dichlorobenzoic acid used in Example 16 with phenoxyacetic acid (100.0 mg, 0.6 mmol), and otherwise referring to Example 16, compound 1C-9 (139.0 mg, yield: 75%) was obtained.
[0119] The preparation of compound 1D-9 is based on the preparation of compound 1D-1 in Example 12.
[0120] Example 21
[0121]
[0122] By replacing 2,3-dichlorobenzoic acid used in Example 16 with 2,4-dichlorophenoxyacetic acid (135.0 mg, 0.6 mmol), and otherwise referring to Example 16, compound 1C-10 (125.0 mg, yield: 70%) was obtained.
[0123] The preparation of compound 1D-10 is based on the preparation of compound 1D-1 in Example 12.
[0124] Example 22
[0125]
[0126] Weigh intermediate c (163.0 mg, 0.6 mmol), 2,3,4-trimethoxybenzoic acid (compound 4) (100.0 mg, 0.5 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 ml, 2.0 mmol), and proceed as with compound 1A-4 to obtain 1C-11 (134.0 mg, yield: 70%).
[0127] The preparation of compound 1D-11 is based on the preparation of compound 1D-1 in Example 12.
[0128] Example 23
[0129]
[0130] 3,4-Dimethoxybenzoic acid (compound 5) (100.0 mg, 0.5 mmol), 1-(2-chlorophenyl)piperazine (120.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), DIEA (1.0 ml, 2.0 mmol), were administered according to the same method as compound 1A-4 to give compound 2A-1 (126.0 mg, yield: 71%).
[0131] Compound 2A-1 (100.0 mg, 0.3 mmol) and a DCM solution of BBr3 (6.0 ml, 3.0 mmol) were prepared using the same method as compound 1B-1 in Example 1 to obtain 2B-1.
[0132] Example 24
[0133]
[0134] By replacing the 1-(2-chlorophenyl)piperazine used in Example 23 with 1-(3-chlorophenyl)piperazine (120.0 mg, 0.6 mmol), and otherwise referring to Example 23, compound 2A-2 (121.0 mg, yield: 60%) was obtained.
[0135] The preparation of compound 2B-2 is based on the preparation of compound 2B-1 in Example 23.
[0136] Example 25
[0137]
[0138] By substituting 1-(2-chlorophenyl)piperazine (140.0 mg, 0.6 mmol) for 1-(2-chlorophenyl)piperazine used in Example 23, and otherwise referring to Example 23, compound 2A-3 (135.0 mg, yield: 72%) was obtained.
[0139] The preparation of compound 2B-3 is based on the preparation of compound 2B-1 in Example 23.
[0140] Example 26
[0141]
[0142] By replacing 1-(2-chlorophenyl)piperazine used in Example 23 with 4,4'-difluorodiphenylpiperazine (173.0 mg, 0.6 mmol), and otherwise referring to Example 23, compound 2A-4 (125.0 mg, yield: 50%) was obtained.
[0143] The preparation of compound 2B-4 is based on the preparation of compound 2B-1 in Example 23.
[0144] Example 27
[0145]
[0146] 3,4-Dimethoxybenzoic acid (compound 5) (100.0 mg, 0.5 mmol), N-Boc-piperazine (150.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), DIEA (1.0 ml, 2.0 mmol), were prepared by recrystallization from 95% EtOH, as in compounds 1A-4, to give intermediate g.
[0147] Intermediate g (125.0 mg, 0.5 mmol), 2,3-dichlorobenzoic acid (115.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), DIEA (1.0 ml, 2.0 mmol), were prepared according to the same method as compound 1A-4 to give 2A-5 (128.0 mg, yield: 65%).
[0148] The preparation of compound 2B-5 is based on the preparation of compound 2B-1 in Example 23.
[0149] Example 28
[0150]
[0151] By replacing the 2,3-dichlorobenzoic acid used in Example 27 with 3,4-dichlorobenzoic acid (115.0 mg, 0.6 mmol), and otherwise referring to Example 27, compound 2A-6 (112 mg, yield: 70%) was obtained.
[0152] The preparation of compound 2B-6 is based on the preparation of compound 2B-1 in Example 23.
[0153] Example 29
[0154]
[0155] By replacing 2,3-dichlorobenzoic acid used in Example 27 with 3,4,5-trifluorobenzoic acid (110.0 mg, 0.6 mmol), and otherwise referring to Example 27, compound 2A-7 (126.0 mg, yield: 66%) was obtained.
[0156] The preparation of compound 2B-7 is based on the preparation of compound 2B-1 in Example 23.
[0157] Example 30
[0158]
[0159] By replacing 2,3-dichlorobenzoic acid used in Example 27 with trans-cinnamic acid (100.0 mg, 0.6 mmol), and otherwise referring to Example 27, compound 2A-8 (104.0 mg, yield: 50%) was obtained.
[0160] The preparation of compound 2B-8 is based on the preparation of compound 2B-1 in Example 23.
[0161] Example 31
[0162]
[0163] By replacing 2,3-dichlorobenzoic acid used in Example 27 with phenoxyacetic acid (100.0 mg, 0.6 mmol), and otherwise referring to Example 27, compound 2A-9 (130.0 mg, yield: 66%) was obtained.
[0164] The preparation of compound 2B-9 is based on the preparation of compound 2B-1 in Example 23.
[0165] Example 32
[0166]
[0167] By replacing 2,3-dichlorobenzoic acid used in Example 27 with 2,4-dichlorophenoxyacetic acid (135.0 mg, 0.6 mmol), and otherwise referring to Example 27, compound 2A-10 (116.0 mg, yield: 60%) was obtained.
[0168] The preparation of compound 2B-10 is based on the preparation of compound 2B-1 in Example 23.
[0169] Example 33
[0170]
[0171] 2,3-Dimethoxybenzoic acid (compound 6) (100.0 mg, 0.5 mmol), 1-(2-chlorophenyl)piperazine (120.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), DIEA (1.0 ml, 2.0 mmol), were prepared by the same method as compound 1A-4 in Example 4 to give 2C-1 (116.0 mg, yield: 65%).
[0172] Weigh 100.0 mg (0.3 mmol) of 2C-1 and a DCM solution of BBr3 (6.0 ml, 3.0 mmol), and obtain 2D-1 by the same method as compound 1B-1 in Example 1.
[0173] Example 34
[0174]
[0175] The compound 2C-2 (113.0 mg, yield: 60%) was obtained by replacing 1-(2-chlorophenyl)piperazine (120.0 mg, 0.6 mmol) in Example 33 with 1-(3-chlorophenyl)piperazine (120.0 mg, 0.6 mmol) in other ways as in Example 33.
[0176] The preparation of compound 2D-2 is the same as that of compound 2D-1 in Example 33.
[0177] Example 35
[0178]
[0179] The compound 2C-3 (136.0 mg, yield: 77%) was obtained by replacing 1-(2-chlorophenyl)piperazine (140.0 mg, 0.6 mmol) in Example 33 with 1-(2,3-dichlorophenyl)piperazine (140.0 mg, 0.6 mmol) in other ways as in Example 33.
[0180] The preparation of compound 2D-3 is based on the preparation of compound 2D-1 in Example 33.
[0181] Example 36
[0182]
[0183] The compound 2C-4 (126.0 mg, yield: 50%) was obtained by replacing 1-(2-chlorophenyl)piperazine used in Example 33 with 4,4'-difluorodiphenylpiperazine (173.0 mg, 0.6 mmol), otherwise following the same procedure as in Example 33.
[0184] The preparation of compound 2D-4 is based on the preparation of compound 2D-1 in Example 33.
[0185] Example 37
[0186]
[0187] 2,3-Dimethoxybenzoic acid (compound 6) (100.0 mg, 0.5 mmol), N-Boc-piperazine (150.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), DIEA (1.0 ml, 2.0 mmol) were administered in the same manner as compounds 1A-4 in Example 4 to obtain intermediate i.
[0188] Weigh intermediate i (150.0 mg, 0.5 mmol), 2,3-dichlorobenzoic acid (compound 5) (115.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 ml, 2.0 mmol), and proceed as in compound 1A-4 in Example 4 to obtain 2C-5 (129.0 mg, yield: 70%).
[0189] The preparation of compound 2D-5 is based on the preparation of compound 2D-1 in Example 33.
[0190] Example 38
[0191]
[0192] By replacing 2,3-dichlorobenzoic acid used in Example 35 with 3,4,5-trifluorobenzoic acid (110.0 mg, 0.6 mmol), and otherwise referring to Example 35, compound 2C-7 (114.0 mg, yield: 72%) was obtained.
[0193] The preparation of compound 2D-7 is based on the preparation of compound 2D-1 in Example 33.
[0194] Example 39
[0195]
[0196] By replacing 2,3-dichlorobenzoic acid used in Example 35 with trans-cinnamic acid (100.0 mg, 0.6 mmol), and otherwise following the same procedure as in Example 35, compound 2C-8 (126.0 mg, yield: 66%) was obtained.
[0197] The preparation of compound 2D-8 is based on the preparation of compound 2D-1 in Example 33.
[0198] Example 40
[0199]
[0200] By replacing 2,3-dichlorobenzoic acid used in Example 35 with 2,4-dichlorophenoxyacetic acid (135.0 mg, 0.6 mmol), and otherwise referring to Example 35, compound 2C-10 (123.0 mg, yield: 60%) was obtained.
[0201] The preparation of compound 2D-10 is based on the preparation of compound 2D-1 in Example 33.
[0202] Example 41
[0203] Synthetic method of compound (4-(2,3-dichlorophenyl)piperazin-1-yl)(3-methoxyphenyl)methanone (3B-3)
[0204]
[0205] 3-Methoxybenzoic acid (compound 9) (100.0 mg, 0.65 mmol), 1-(2,3-dichlorophenyl)piperazine (139.0 mg, 0.8 mmol), PyBOP (416.3 mg, 0.8 mmol), DIEA (1.0 ml, 2.0 mmol), were administered in the same manner as compound 1A-4 in Example 4 to give 3B-3 (126 mg, yield: 79%).
[0206] The structures, NMR, MS, and cell infection rates of the compounds prepared in Examples 1–41 are shown in Table 1.
[0207] Table 1
[0208]
[0209]
[0210]
[0211]
[0212]
[0213]
[0214]
[0215]
[0216]
[0217]
[0218]
[0219]
[0220] Example 42: Synthesis method of MZD-8:
[0221]
[0222] 3,4-Methylenedioxyphenylacrylic acid (96.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, 1-chlorodiphenylmethylpiperazine (171.7 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-8 (57.7 mg, yield: 60%) was obtained.
[0223] Example 43: Synthesis method of MZD-35:
[0224]
[0225] 4-Fluorophenylacrylic acid (83.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, diphenylmethylpiperazine (151.3 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-35 (118.0 mg, yield: 60%) was obtained.
[0226] Example 44: Synthesis method of MZD-57:
[0227]
[0228] 4-Methylphenylacrylic acid (81.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, 4,4'-difluorobenzoperazine (173.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-57 (60.8 mg, yield: 75%) was obtained.
[0229] Example 45: Synthesis method of MZD-56:
[0230]
[0231] 4-Methylphenylacrylic acid (81.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, 1-chlorodiphenylmethylpiperazine (171.7 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-56 (48.7 mg, yield: 60%) was obtained.
[0232] Example 46: Synthesis method of MZD-37:
[0233]
[0234] 4-Fluorophenylacrylic acid (83.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, 4,4'-difluorophenylpiperazine (173.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-37 (66.5 mg, yield: 80%) was obtained.
[0235] Example 47: Synthesis method of MZD-36:
[0236]
[0237] 4-Fluorophenylacrylic acid (83.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, 1-chlorodiphenylmethylpiperazine (171.7 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-36 (49.9 mg, yield: 60%) was obtained.
[0238] Example 48: Synthesis method of MZD-43:
[0239]
[0240] 2-Fluorophenylacrylic acid (83.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, diphenylmethylpiperazine (151.3 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-43 (49.9 mg, yield: 60%) was obtained.
[0241] Example 49: Synthesis method of MZD-40:
[0242]
[0243] 3-Fluorophenylacrylic acid (83.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, 1-chlorodiphenylmethylpiperazine (171.7 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-40 (49.9 mg, yield: 60%) was obtained.
[0244] Example 50: Synthesis method of MZD-55:
[0245]
[0246] 4-Methylphenylacrylic acid (81.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, diphenylmethylpiperazine (151.3 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-55 (48.7 mg, yield: 60%) was obtained.
[0247] Example 51: Synthesis method of MZD-44:
[0248]
[0249] 2-Fluorophenylacrylic acid (83.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, 1-chlorodiphenylmethylpiperazine (171.7 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-44 (49.9 mg, yield: 60%) was obtained.
[0250] Example 52: Synthesis method of MZD-39:
[0251]
[0252] 3-Fluorophenylacrylic acid (83.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, diphenylmethylpiperazine (151.3 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-39 (49.9 mg, yield: 60%) was obtained.
[0253] Example 53: Synthesis method of MZD-9:
[0254]
[0255] 3,4-Methylenedioxyphenylacrylic acid (96.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, 4,4'-difluorobenzoperazine (173.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-9 (57.7 mg, yield: 60%) was obtained.
[0256] Example 54: Synthesis method of MZD-45:
[0257]
[0258] 2-Fluorophenylacrylic acid (83.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, 4,4'-difluorophenylpiperazine (173.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-45 (49.9 mg, yield: 60%) was obtained.
[0259] Example 55: Synthesis method of MZD-41:
[0260]
[0261] 3-Fluorophenylacrylic acid (83.1 mg, 0.5 mmol) was placed in a 100 mL round-bottom flask, and DMF (10.0 mL) was added to dissolve it. Then, 4,4'-difluorophenylpiperazine (173.0 mg, 0.6 mmol), PyBOP (312.2 mg, 0.6 mmol), and DIEA (1.0 mL, 2.0 mmol) were added sequentially. After the addition was complete, the mixture was stirred at room temperature for 4 h, and the reaction was monitored by TLC (DCM:MeOH = 10:1). After the reaction was complete, 100.0 mL of water was added to quench the reaction, and the mixture was stirred at room temperature for 1 h. If solid precipitation occurred, the mixture was filtered, and the filter cake was dried in an oven. After recrystallization with 95% EtOH, compound MZD-41 (49.9 mg, yield: 60%) was obtained.
[0262] The structures, NMR, MS, and cell infection rates of the compounds prepared in Examples 42–55 are shown in Table 2.
[0263] Table 2
[0264]
[0265]
[0266] Example 56
[0267] Experimental methods for the anti-CHIKV effects of some compounds
[0268] (I) Experimental drugs, reagents and materials
[0269] 1. Human hepatocellular carcinoma cells Huh7 were purchased from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences, and preserved by the Department of Biomedical Defense, Naval Medical University of the Chinese People's Liberation Army.
[0270] 2. DMEM complete cell culture medium containing 10% fetal bovine serum, 0.03% glutamine, non-essential amino acids, ampicillin and streptomycin 100 U / mL, adjusted to pH 7.4.
[0271] 3. Cell digestion solution containing 0.25% trypsin, prepared with phosphate buffer.
[0272] (II) Virus
[0273] Chikungunya virus (CHIKV) strain LR2006 was synthesized. The genome of this virus was then inserted between the non-structural and structural genes into an EGFP expression cassette (using the CHIKV structural gene promoter as the EGFP promoter). The resulting recombinant virus LR2006-EGFP showed obvious green fluorescence 8 hours after infecting Huh7 cells.
[0274] (III) Evaluation of antiviral activity
[0275] 1. Cell seeding: Prepare multiple bottles of Huh7 cells in good growth condition, wash with PBS, digest with trypsin, suspend the cells in DMEM culture medium containing 10% FBS, mix the cells, and seed them into 96-well plates with 100 μl of cell suspension per well, 15,000 cells per well. Culture for 12 hours, at which point the cells are 100% confluenced, and then proceed with drug treatment and viral infection.
[0276] 2. Viral infection: Place the 96-well plate in a 4°C freezer. Dilute the five viruses with DMEM culture medium containing 10% FBS to a multiplicity of infection (MOI) of 0.1 per well according to the previously determined titers of the five viruses. Mix the virus thoroughly, then remove the 96-well plate from the 4°C freezer, add 50 μl of virus diluent, and place it in a 4°C freezer.
[0277] 3. Drug treatment: Add 250 μl of DMEM complete culture medium to each well of a 96-well plate, and add an appropriate amount of drug diluent to each well to achieve a final drug concentration of 10 μM. Shake thoroughly on a shaker for 5 min, then incubate at 37°C for cell culture. DMSO was used as a negative control.
[0278] 4. Viral infection detection: 12 hours after CHIKV infection, four fields of view were photographed per well using an EVOS M7000 cell imaging system, and the number of EGFP-positive cells was counted. The cell infection rate after treatment with a 10 μM concentration of compound was determined.
[0279] Cell infection rate data are shown in Table 3:
[0280] Table 3
[0281] serial number Cell infection rate % 1A-1 13 1B-1 2.8 1C-1 3.5 1D-1 2.7 2A-1 4 2B-1 2.1 2C-1 3.1 2D-1 2.7 1A-2 5.7 1B-2 3.0 1C-2 4.9 1D-2 2.5 2A-2 6.4 2C-2 3.2 2D-2 3.3 1B-3 3.4 1C-3 3.8 1D-3 1.6 2A-3 4.1 2B-3 2.7 2C-3 4.7 2D-3 3.9
[0282] The data above show that the compounds of this invention exhibit a very low cell infection rate. Generally, an infection rate of 50% or less is considered effective. Therefore, the compounds prepared in the embodiments of this invention all demonstrate excellent inhibitory activity against CHIKV and can be used as anti-Chikungunya virus drugs.
[0283] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any way. Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Any person skilled in the art can make some modifications or alterations to the above-described technical content to create equivalent embodiments without departing from the scope of the present invention. Any simple modifications, equivalent changes, and alterations made to the above embodiments based on the technical essence of the present invention without departing from the scope of the present invention shall still fall within the scope of the present invention.
Claims
1. A class of substituted benzoylpiperazine compounds or their pharmaceutical salts, characterized in that, The substituted benzoylpiperazine compound has one of the following structures: 。 2. The use of a substituted benzoylpiperazine compound or its pharmaceutical salt in the preparation of an anti-Chikungunya virus drug, characterized in that, The substituted benzoylpiperazine compound has one of the following structures: ; ; ; ; 。
Citation Information
Patent Citations
A class of substituted benzoylpiperazine compounds and their application in the preparation of anti-chikungunya virus drugs
CN115417834B
Substituted piperazine and piperidine calcium channel blockers
CN1411374A
